Visit the original URL
Sinopharm Holdings announced on January 2 that the company’s controlling shareholder, China National Pharmaceutical Group Co., Ltd., has signed a cooperation framework agreement with Merck in September 2022, and has been granted the anti-new coronavirus oral drug monogravir jointly developed by Merck and Ridgeback Biotechnology Distribution rights and exclusive import rights for capsules (trade name: LAGEVRIO®) (Monoravir) in mainland China. In November 2022, Sinopharm Holdings Distribution Center Co., Ltd., a subsidiary of the company, signed a distribution agreement with Merck, and will be responsible for the import and distribution of monogravir in mainland China during the agreement period. The final use and sales of the products are affected by factors such as the epidemic, and there are great uncertainties. Monogravir is the world’s first approved oral anti-new coronavirus drug, and it has obtained marketing authorization or emergency user license in more than 40 countries or regions. With the approval of monogravir in China this time, the company will work closely with Merck to pool the strengths of both parties to accelerate the launch and supply of the drug, so as to benefit Chinese patients in need as soon as possible. (interface)
media reports
36Kr interface titanium media
related events
- Sinopharm Holdings: Cooperating with Merck to promote the launch and supply of anti-new coronavirus oral drug Ridrovir (Monoravir Capsules) in mainland China2023-01-02
- Sinopharm Online announced that it has obtained 300 million yuan in Series B financing2019-04-26
- Sinopharm Online received RMB 120 million in Series A financing from Yunfeng Fund and Lanxess2017-07-05
This article is transferred from: https://readhub.cn/topic/8mfEGUZ9mGk
This site is only for collection, and the copyright belongs to the original author.